Clinical trials: Moderate COPD
Heart Failure, Chronic Obstructive Pulmonary Disease
Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease
The principal research objectives are to demonstrate cardioselective beta-blockade using bisoprolol is not inferior to placebo with regard to pulmonary function and improves quality of life in patients with heart failure and…
- Trial name
- NCT00702156
- Testing
- Bisoprolol
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- NHS Greater Glasgow and Clyde
COPD
Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD
Preliminary information from our laboratory indicated that even patients with milder chronic obstructive pulmonary disease (COPD) can have significant physiological derangements which become more pronounced during exercise…
- Trial name
- NCT01491802
- Testing
- LAMA/LABA, LAMA
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Queen's University
Chronic Obstructive Pulmonary Disease
Rehabilitation in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD)
The study is a single-center randomized, unblinded, placebo-controlled study to investigate the effect of pulmonary rehabilitation in subjects with moderate chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01320930
- Testing
- Pulmonary rehabilitation, conventional care
- Volunteers
- 61 people
- Sponsor
- Bispebjerg Hospital
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.
- Trial name
- iCHOROS (NCT07069829)
- Where
- 36 sites in Argentina, Colombia and 10 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487446
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 58 sites in United States
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST2 (NCT00877383)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 176 sites in United States, Canada and 7 more
- Volunteers
- 1,142 people
- Sponsor
- Novartis Pharmaceuticals
Asthma COPD
Single and Multiple Ascending Dose Study of KN-002
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 4 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in…
- Trial name
- KN-002 (NCT05006521)
- Testing
- KN-002
- Where
- United Kingdom
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Kinaset Therapeutics Inc
Chronic Obstructive Pulmonary Disease COPD
Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871
This is a study to evaluate the effects of AZD8871 in patients with COPD. Adult male or female patients with moderate to severe COPD, who agree to be in this study, will receive 3 treatments, i.e.
- Trial name
- NCT02971293
- Testing
- AZD8871 100 µg, AZD8871 600 µg
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease: COPD
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
The study purpose is to evaluate the effect of QAB149 NVA237 vs. QAB149 on static lung hyperinflation.
- Trial name
- SYNERGY (NCT01699685)
- Testing
- QAB149, NVA237
- Where
- 11 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal and sub-optimal Peak Inspiratory Flow…
- Trial name
- NCT04223843
- Testing
- Tiotropium + olodaterol
- Where
- 26 sites in United States, Germany
- Volunteers
- 213 people
- Sponsor
- Boehringer Ingelheim
COPD
Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange
To evaluate the role of inhaled corticosteroids to suppress nitric oxide gas exchange in stable patients with moderate-to-severe COPD who are current non-smokers and not on oral corticosteroids.
- Trial name
- NCT00568347
- Testing
- fluticasone 100mcg/ salmeterol 50mcg, fluticasone 250/salmeterol 50, salmeterol
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Arthur F Gelb MD
Chronic Obstructive Pulmonary Disease
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and…
- Trial name
- FAST (NCT01922271)
- Testing
- NVA237, Tiotropium, Salbutamol
- Where
- 14 sites in Germany
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
- Trial name
- NCT00622635
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Use of Wii Home Computer in Patients With Chronic Obstructive Pulmonary Disease: Effects on Quality of Life
This study was designed to evaluate the effectiveness of 12 weeks' home exercise training using the Nintendo ® Wii Fit system in patients with COPD.
- Trial name
- NCT01539421
- Testing
- Use of Home exercise computer program
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Trinity Health Of New England
Asthma, Reactive Airway Disease
Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma
This study seeks to compare the effectiveness of a single dose of oral dexamethasone versus 5 days of oral prednisone in the treatment of mild to moderate asthma exacerbations to prevent relapse with an unscheduled return visit…
- Trial name
- NCT01241006
- Testing
- Dexamethasone, Prednisone
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Alameda County Medical Center
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of the study is to evaluate the effect of CNTO6785 compared with placebo in participants with moderate to severe Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT01966549
- Testing
- CNTO 6785
- Where
- 44 sites in Czechia, Germany and 6 more
- Volunteers
- 187 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase IIa, open-label, repeat-dose trial to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide/Formoterol Fumarate 400/12 μg in 20 Chinese male…
- Trial name
- NCT03276078
- Testing
- Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
- Where
- China
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Indacaterol EfectIveness In COPD Patients With Tuberculosis History
This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.
- Trial name
- INFINITY (NCT01778062)
- Testing
- Indacaterol, Control
- Where
- 13 sites in South Korea
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic
Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
When using the Breathe Technologies Ventilation System during simulated activities of daily living (ADLs), Subjects with moderate-to-severe chronic obstructive pulmonary Disease (COPD) will be comfortable and report acceptability.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
- Trial name
- PRIDE (NCT01355978)
- Testing
- Noninvasive Open Ventilation System
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Breathe Technologies, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol
In this 5-months study, the response of patients to salbutamol at baseline will be compared with their response to treatment with indacaterol.
- Trial name
- REVERBREZ (NCT01272362)
- Testing
- Indacaterol
- Where
- 137 sites in France
- Volunteers
- 625 people
- Sponsor
- Novartis Pharmaceuticals